Studies of berberine in people
38 studies gave berberine to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on visceral adipose tissue area1.38% [97.5% CI, −2.43% to 5.18%] no change: Has no effect on liver fat content0.87% [97.5% CI, −0.39% to 2.13%] down: Decreases low-density lipoprotein cholesterol−7.72 [95% CI, −13.13 to −1.93] mg/dL | Randomized trial6 months | 337 people116 (34.4%) were female, and 221 (65.6%) were malemean (SD) age was 41.8 (10.6) yearsDiabetes-free individuals with obesity and MASLD | JAMA network open, Jan 2, 2026 |
up: Increases VEGFA down: Decreases pulse wave analysis systolic pressure134.85 ± 16.26 before and 124.46 ± 13.47 after no change: Has no effect on arterial stiffness | Randomized trial12 weeks | 70 people40 to 60 yearsPatients with MAFLD | Nutrients, Nov 16, 2025 |
down: Decreases colorectal adenoma recurrenceadjusted HR 0.58, 95% CI 0.45–0.74 down: Decreases colorectal neoplasm occurrenceadjusted HR 0.75, 95% CI 0.62–0.91 | Treated cohort2 years | 648 peoplePatients aged 18–75 years who had undergone endoscopic polypectomy six months before recruitment | Cell reports. Medicine, Aug 11, 2025 |
down: Decreases homeostatic model assessment of insulin resistance0.51 ≤ ES ≤0.54 | Randomized trial8 weeks | 64 peoplemenmiddle-agedMiddle-aged men with overweight or obesity and varying glycemic levels | Physiological reports, Aug 1, 2024 |
down: Decreases alanine transaminasep=0.0105 down: Decreases de Ritis ratiop=0.0011 down: Decreases total cholesterolp=0.0009 | Randomized trial12 weeks | 70 peopleMAFLD | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, Jul 18, 2024 |
down: Decreases blood pressure down: Decreases body weight | Randomized trial3 months | 50 peopleadultPatients diagnosed with exogenous obesity | Nutrients, Jul 16, 2024 |
down: Decreases fasting blood glucose5.33 ± 0.28 vs 6.16 ± 0.44 mmol/L down: Decreases HOMA-IR2.41 ± 0.14 vs 3.40 ± 0.28 units | Randomized trial84 days | 34 peopleIndividuals with prediabetes fulfilling the inclusion and exclusion criteria | BMC endocrine disorders, Sep 7, 2023 |
down: Decreases body weight down: Decreases TNF-alpha | Randomized trial20 weeks | 43 peoplePeople living with HIV under virological suppression and metabolic syndrome | International journal of STD & AIDS, Aug 23, 2023 |
down: Decreases glycemiaβ=-0.2495 (95% CI -0.47; -0.06), p=0.004 down: Decreases total cholesterolβ=-0.25 (95% CI -0.45; -0.04), p=0.05 down: Decreases visceral adipose tissueβ=-91.50 (95% CI -132.60; -48.19), p<0.0001 | Randomized trialtwo months | 49 peopleBothIn overweight subjects with impaired fasting blood glucose, versus placebo | European review for medical and pharmacological sciences, Jul 1, 2023 |
down: Decreases body weightMD -1.08, 95% CI -1.76 to -0.40, P = 0.002, d = 0.59 down: Decreases total cholesterolMD -0.58, 95% CI -0.74 to -0.41, P < 0.001, d = 1.31 | Randomized trial12 weeks | 113 peopleSchizophrenia spectrum disorders with metabolic syndrome | Psychiatry and clinical neurosciences, Jan 18, 2022 |
down: Decreases body weight-1.10 kg vs +1.45 kg, P = 0.001 down: Decreases leptinFtime*group=6.265, P = 0.003 no change: Has no effect on adiponectin | Randomized trial8-week | 49 peopleIn patients with schizophrenia on stable antipsychotic treatment | Asian journal of psychiatry, Nov 1, 2021 |
up: Increases insulin secretion no change: Has no effect on basal insulin secretion | Randomized trial160-min clamp, 14-day follow up | 15 peopleMenGeneral population; under hyperglycemic state during hyperglycemic clamp | Nature communications, Sep 23, 2021 |
down: Decreases fasting plasma glucoseLS mean difference −0.50 mmol/L (95% CI −0.85 to −0.15) | Randomized trial16 weeks | 297 people18-70 yearsNewly diagnosed patients with hyperglycemia | Genome medicine, Aug 9, 2021 |
down: Decreases total cholesterol down: Decreases HDL-C no change: Has no effect on blood pressure | Randomized trial12 weeks | 84 peoplemen20 to 65 yearsEligible men | Nutrients, Jul 26, 2021 |
down: Decreases total cholesterolall p<0.05 down: Decreases low-density lipoprotein cholesterolall p<0.05 down: Decreases insulin resistanceall p<0.05 | Randomized trial8 weeks | 49 peopleAdjunctive treatment | Psychiatry research, Mar 23, 2021 |
down: Decreases HOMA-IR | Randomized trial12 weeks | 132 peopleMild metabolic disorders induced by olanzapine | The American journal of Chinese medicine, Jan 1, 2021 |
down: Decreases HbA1c−0.99 [−1.16, −0.83]% vs −0.59 [−0.75, −0.44]% up: Increases gastrointestinal side effects | Randomized trial12 weeks | 409 peopleParticipants with newly diagnosed type 2 diabetes who were drug naive for glycemic control with at least 2 months of stable lifestyle intervention | Nature communications, Oct 6, 2020 |
| Randomized trial90 days | 12 people30-60 yearsMidlife adults; mixed dyslipidemia | Journal of medicinal food, May 12, 2020 | |
down: Lowers the risk of colorectal adenoma recurrenceRR 0.77 (95% CI 0.66-0.91), 36% vs 47% up: Increases constipation1% vs <0.5% | Randomized trialup to 2 years | 18-75 yearsGeneral population; Midlife adults; Older adults; after complete polypectomy of colorectal adenomas | The lancet. Gastroenterology & hepatology, Jan 8, 2020 |
down: Decreases Geboes grade | Randomized trial3 months | On mesalamine | Cancer prevention research (Philadelphia, Pa.), Oct 16, 2019 |
up: Increases brown adipose tissue mass and activity down: Decreases body weight up: Improves insulin sensitivity | Trial1 month | Mildly overweight patients with non-alcoholic fatty liver disease | Cell death & disease, Jun 13, 2019 |
down: Decreases urine albumin-creatinine ratio47(26, 120) mg/g vs 68(28, 158) mg/g, P=0.039 down: Decreases cystatin C(0.83±0.30) mg/L vs (0.96±0.30)mg/L, P=0.041 down: Protects against diabetic kidney disease | Randomized trialsix months | 114 peopleBoth(55±14) yearsMidlife adults; type 2 diabetes mellitus | Zhonghua yi xue za zhi, Dec 11, 2018 |
| Randomized trial3 successive months | 97 peopleMild hyperlipidemia | Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, Jun 1, 2016 | |
down: Decreases hepatic fat52.7% vs 36.4% down: Decreases body weightp<0.05 down: Decreases HOMA-IRp<0.05 | Randomized trial16 weeks | 184 peoplePatient cohorts | PloS one, Aug 7, 2015 |
down: Lowers the risk of severe ovarian hyperstimulation syndrome up: Improves live birth rate | Randomized trial3 months | 150 peopleWomenIn infertile women with PCOS undergoing IVF treatment | Clinical endocrinology, Aug 9, 2013 |
down: Decreases metabolic syndromeremission of 36% (P=0.037) up: Improves insulin sensitivity2.1±1.0 vs. 3.1±1.6, P<0.01 down: Decreases total insulin secretion92,056±72,148 vs. 67,407±46,441 pmol/L, P<0.01 | Randomized trial3 months | 24 peopleBothPatients with metabolic syndrome | Metabolic syndrome and related disorders, Jun 28, 2013 |
down: Decreases LDL cholesterol up: Increases HDL cholesterol | Randomized trial3 months | 144 peopleGeneral population | Expert opinion on biological therapy, Feb 27, 2013 |
| Randomized trialsix months | 270 peopleSubjects with primary polygenic HCH who had a negative history of cardiovascular disease and were previously found to be intolerant to STs or were refusing treatment with these drugs | Lipids in health and disease, Sep 22, 2012 | |
down: Decreases body weightaverage 5 lb/subject down: Decreases blood lipids23% decrease of triglyceride and 12.2% decrease of cholesterol levels | Trial12 weeks | Obese | Phytomedicine : international journal of phytotherapy and phytopharmacology, Jun 26, 2012 |
down: Decreases MMP9 | Trial30 days | 130 peopleIn ACS patients following PCI | Clinical and experimental pharmacology & physiology, May 1, 2012 |
down: Decreases metabolic dysfunction-associated steatotic liver disease70% effective rate down: Decreases alanine aminotransferase down: Decreases total cholesterol | Randomized trial12 weeks | 60 peopleNew diagnosed type 2 diabetes combining nonalcoholic fatty liver disease | Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, Nov 1, 2011 |
down: Decreases waist circumferenceP<0.01 down: Decreases low-density lipoprotein cholesterolP<0.05 down: Decreases homeostasis model assessment for IRP<0.05 | Randomized trial3 months | 89 peopleWomenIn women with PCOS and IR receiving compound cyproterone acetate | European journal of endocrinology, Oct 21, 2011 |
| Randomized trial | 60 peopleType 2 diabetes and dyslipidemia | Talanta, Jan 18, 2010 | |
| Randomized trial | Type 2 diabetes mellitus | Metabolism: clinical and experimental, Oct 1, 2009 | |
down: Decreases CD31+/CD42- microparticles up: Improves flow-mediated vasodilation no change: Has no effect on nitroglyceride-mediated vasodilation | Trial1-month | 14 peopleGeneral population | European journal of pharmacology, May 3, 2009 |
down: Decreases HbA1cfrom 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01 down: Decreases triglyceridefrom 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05 down: Decreases HOMA-IRreduced by 44.7% (P<.001) | Randomized trial3 months | 36 peopleNewly diagnosed type 2 diabetes mellitus | Metabolism: clinical and experimental, May 1, 2008 |
down: Decreases HbA1cHbA1c from 7.5 +/- 1.0% to 6.6 +/- 0.7%, P < 0.0001 vs placebo down: Decreases LDL cholesterolfrom 3.23 +/- 0.81 to 2.55 +/- 0.77 mm/liter, P < 0.0001 vs placebo no change: Has no effect on insulin sensitivityP = 0.063 vs placebo | Randomized trial3 months | 116 peopleIn type 2 diabetic patients with dyslipidemia | The Journal of clinical endocrinology and metabolism, Apr 8, 2008 |
down: Decreases LDL cholesterol-25% | Trial3 months | 32 peopleHypercholesterolemia | Nature medicine, Nov 7, 2004 |